Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors.
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)
1 trial -
Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer
Janssen-Cilag International N.V.
Localized Bladder Cancer
1 trial -
Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo
Non-small cell lung cancer
1 trial -
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer
Amgen
Small Cell Lung Cancer
1 trial -
Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)
Amgen
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).
The George Institute
Non-small cell lung cancer (NSCLC)
1 trial -
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
Novartis Pharmaceuticals
Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)
1 trial -
Phase I study of 225Ac-PSMA I&T in prostate cancer
Disc Medicine
metastatic prostate cancer
1 trial -
Phase I study of MGY825 in patients with lung cancer
Novartis Pharmaceuticals
Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3 mutations in adult patients
1 trial -
Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. (The CPD-DARA Study).
Ningbo Cancer Hospital
Relapsed/ refractory multiple myeloma
1 trial -
Pilot Study on Subcutaneously Administered Immunotherapy for the Treatment of Cervical Cancer
Disc Medicine
Cervical Cancer
1 trial -
Pluvicto 1 000 MBq/mL solution for injection/infusion, Lutetium (177Lu) rhPSMA-10.1 injection
Blue Earth Diagnostics Ireland Ltd
PSMA-positive non-curative metastatic castration-resistant prostate cancer
1 trial -
Prospective feasibility pilot study evaluating the value of [68Ga]Ga-PENTIXAFOR PET-CT in patients with locally advanced or metastatic Small Cell Lung Cancer (SCLC) at diagnosis and disease progression (PASSIFLORE)
CERO THERAPEUTICS HOLDINGS, INC.
cell lung carcinoma
1 trial -
Proxalutamide
The First People's Hospital of Lianyungang
Metastatic Breast Cancer
1 trial -
Pyrotinib low dose group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
REGN1400
Regeneron UK Limited
Cancer
1 trial -
REGN5678
Regeneron UK Limited
Prostate Cancer
1 trial -
REOLYSIN®
ONCOLYTICS BIOTECH INC
KRAS Mutant Metastatic Colorectal Cancer
1 trial -
RESTART; Autologous Transplantation of Adult Salivary Gland Stem Cells to Restore Submandibular Gland Function after Radiotherapy
Disc Medicine
Patients operated with curative intend for head and neck cancer with an indication for bilateral postoperative radiotherapy, with or without chemotherapy.
1 trial -
RMC-5127
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
RMC-6291
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC)
2 trials -
RMC-9805
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
Repurposed Drugs in Research and Cancer Clinical Trials. The ReDiReCCT trial Vemurafenib
Disc Medicine
Glioma
1 trial -
SCT-001 CAR-T cells
Shanghai University of Traditional Chinese Medicine
Ovarian Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources